We've got you covered
We are here to guide you in making tough decisions with your hard earned money. Drop us your details and we will reach you for a free one on one discussion with our experts.
or
Call us on: +917410000494
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, distributes, and markets pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease and diabetes medicines under the Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN brands; Respiratory medicines under the Symbicort and FASENRA brand names; and oncology medicines under the LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex brands. The company also offers products in the areas of renal, metabolic, and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.
TODAY'S HIGH
3095
TODAY'S LOW
3043
52 WEEK HIGH
3349
52 WEEK LOW
2445.7
% of Shares Held by
All Insider
82.14%
% of Shares Held by
Institutions
2.99%
% of Float Held by
Institutions
16.74%
Number of Institutions
Holding Shares
20
MARKET CAP
7633.74 Cr.
ETERPRISE VALUE
7234.58 Cr.
NO. OF SHARES
2.50 Cr.
BOOK VALUE
204.556
DIV. YIELD
8%
DEBT
8.63 Cr.
GROSS PROFIT
488.70 Cr.
CASH
448.41 Cr.
REVENUE
805.60 Cr.
REVENUE/SHARE
322.24
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Investments | 0 | 169 Cr. | -169 Cr. | 11.68 Cr. |
| Change To Liabilities | 9.67 Cr. | -31.34 Cr. | 41.45 Cr. | 41.04 Cr. |
| Total cashflows from Investing Activities | 4.74 Cr. | 173.03 Cr. | -170.80 Cr. | 4.28 Cr. |
| Net Borrowings | -3.50 Cr. | -2.88 Cr. | -2.21 Cr. | -2.21 Cr. |
| Total Cash from Financing Activities | -9.45 Cr. | -8.97 Cr. | -6.36 Cr. | -6.36 Cr. |
| Other Liabilities | 8.55 Cr. | 26.62 Cr. | 7.75 Cr. | 2.08 Cr. |
| Total Assets | 0 | 0 | 0 | 0 |
| Net Income | 61.59 Cr. | 93.30 Cr. | 72.21 Cr. | 54.45 Cr. |
| Change in Cash | 96.08 Cr. | 268.84 Cr. | -89.74 Cr. | 59.26 Cr. |
| Effect of Exchange Rate | 0 | 0 | 0 | 0 |
| Total Cash from Operating Activities | 100.79 Cr. | 104.78 Cr. | 87.42 Cr. | 54.98 Cr. |
| Depreciation | 16.94 Cr. | 19.75 Cr. | 18.58 Cr. | 14.92 Cr. |
| Other Cashflows from Investing Activities | 11.11 Cr. | 9.32 Cr. | 11.93 Cr. | 11.02 Cr. |
| Dividends Paid | -5 Cr. | -5 Cr. | -2.50 Cr. | -2.50 Cr. |
| Change to Inventory | 19.57 Cr. | 5.35 Cr. | -47.03 Cr. | -4.96 Cr. |
| Change to Account Receivables | -4.90 Cr. | -4.58 Cr. | -4.83 Cr. | -28.35 Cr. |
| Other Cashflows from Financing Activities | -94.72 Lakhs | -1.09 Cr. | -1.65 Cr. | -1.65 Cr. |
| Change to Net Income | -10.65 Cr. | -4.32 Cr. | -71 Lakhs | -24.20 Cr. |
| Capital Expenditures | -9.61 Cr. | -7.71 Cr. | -14.22 Cr. | -18.69 Cr. |
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Research Development | None | None | None | None |
| Effect of Accounting Charges | None | None | None | None |
| Income Before Tax | 83.03 Cr. | 127.09 Cr. | 113.97 Cr. | 72.67 Cr. |
| Minority Interest | None | None | None | None |
| Net Income | 69.22 Cr. | 116.26 Cr. | 102.56 Cr. | 56.57 Cr. |
| Selling General Administrative | 280.92 Cr. | 219.93 Cr. | 217.99 Cr. | 202.67 Cr. |
| Gross Profit | 493.63 Cr. | 512.53 Cr. | 520.17 Cr. | 490.48 Cr. |
| Ebit | 69.22 Cr. | 116.26 Cr. | 102.56 Cr. | 56.57 Cr. |
| Operating Income | 69.22 Cr. | 116.26 Cr. | 102.56 Cr. | 56.57 Cr. |
| Other Operating Expenses | 122.53 Cr. | 153.87 Cr. | 179.46 Cr. | 212.87 Cr. |
| Interest Expense | -94.72 Lakhs | -1.09 Cr. | -1.14 Cr. | -1.14 Cr. |
| Extraordinary Items | None | None | None | None |
| Non Recurring | None | None | None | None |
| Other Items | None | None | None | None |
| Income Tax Expense | 21.44 Cr. | 33.79 Cr. | 41.76 Cr. | 18.22 Cr. |
| Total Revenue | 805.60 Cr. | 813.56 Cr. | 831.81 Cr. | 728.29 Cr. |
| Total Operating Expenses | 736.37 Cr. | 697.30 Cr. | 729.25 Cr. | 671.72 Cr. |
| Cost of Revenue | 311.96 Cr. | 301.03 Cr. | 311.64 Cr. | 237.81 Cr. |
| Total Other Income Expense Net | 13.81 Cr. | 10.83 Cr. | 11.41 Cr. | 16.10 Cr. |
| Discontinued Operations | None | None | None | None |
| Net Income from Continuous Ops. | 61.59 Cr. | 93.30 Cr. | 72.21 Cr. | 54.45 Cr. |
| Net Income Applicable to Common Shares | 61.59 Cr. | 93.30 Cr. | 72.21 Cr. | 54.45 Cr. |
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Intangible Assets | 0 | 0 | 0 | 0 |
| Capital Surplus | 0 | 0 | 0 | 0 |
| Total Liabilities | 345.16 Cr. | 318.54 Cr. | 341.92 Cr. | 261 Cr. |
| Stock Holder Equity | 511.39 Cr. | 456.17 Cr. | 364.44 Cr. | 300.80 Cr. |
| Minority Interest | 0 | 0 | 0 | 0 |
| Other Liabilities | 140.98 Cr. | 34.77 Cr. | 28.24 Cr. | 21.92 Cr. |
| Total Assets | 856.55 Cr. | 774.71 Cr. | 706.36 Cr. | 561.80 Cr. |
| Common Stock | 5 Cr. | 5 Cr. | 5 Cr. | 5 Cr. |
| Retained Earnings | 0 | 377.23 Cr. | 285.50 Cr. | 221.35 Cr. |
| Other Liabilities | 7.49 Cr. | 6.41 Cr. | 5.38 Cr. | 2.02 Cr. |
| Good Will | 0 | 0 | 0 | 0 |
| Treasury Stock | 506.39 Cr. | 73.94 Cr. | 73.94 Cr. | 74.45 Cr. |
| Other Assets | 74.18 Cr. | 70.97 Cr. | 68.27 Cr. | 75.35 Cr. |
| Cash | 448.45 Cr. | 352.34 Cr. | 83.50 Cr. | 173.24 Cr. |
| Current Liabilities | 332.64 Cr. | 303.50 Cr. | 327.24 Cr. | 258.98 Cr. |
| Long Term Asset Charges | 16.28 Cr. | 14.53 Cr. | 14.64 Cr. | 23.36 Cr. |
| Short Long Term Debt | 0 | 0 | 0 | 0 |
| Other Stockholder Equity | 506.39 Cr. | 73.94 Cr. | 73.94 Cr. | 74.45 Cr. |
| Property Plant Equipment | 76.70 Cr. | 84.98 Cr. | 95.77 Cr. | 81.73 Cr. |
| Total Cur. Assets | 705.66 Cr. | 618.76 Cr. | 542.32 Cr. | 404.72 Cr. |
| Long Term Investments | 0 | 0 | 0 | 0 |
| Net Tangible Assets | 511.39 Cr. | 456.17 Cr. | 364.44 Cr. | 300.80 Cr. |
| Short Term Investments | 0 | 0 | 169 Cr. | 0 |
| Net Receivables | 98.24 Cr. | 91.21 Cr. | 95.58 Cr. | 86.12 Cr. |
| Long Term Debt | 0 | 0 | 0 | 0 |
| Inventory | 140.21 Cr. | 159.80 Cr. | 165.15 Cr. | 118.10 Cr. |
| Accounts Payable | 188.05 Cr. | 178.37 Cr. | 209.72 Cr. | 168.20 Cr. |
Open a demat account through us and get the account opening charges waived off
open paperless account